Allergan plc

Allergan gained 14.9% for the week ended October 30, 2015. The company’s stocks gained on the news of a possible merger with Pfizer.

While a section of the market is readying itself for a rate hike in the upcoming meeting of the FOMC, there are others who don’t believe that a rate hike would be implemented and instead, are focused on falling inflation.

If approved, solanezumab would be a breakthrough therapy in the Alzheimer’s market. The drug actually seeks to cure the cognitive disease, not simply treat it.